The PARP inhibitors are expected to increase T cell’s tumor-killing efficacy, and to activate the cancer-immunity cycle thereby increasing the sensitivity of tumor cells toward immune checkpoint blockade [144]. The gene discussed is PARP1; the disease is neoplasm.